电广传媒在互动平台表示，公司旗下达晨财智管理基金规模近660亿元，目前达晨财智旗下管理的基金 累计投资了800余家企业，成功退出301家，主要投资领域包括人工智能、信息技术、生命科技、国防军 工等，基金投资了云深处科技。 ...

公开资料显示，港投公司成立于2022年，是香港特别行政区政府的耐心资本投资平台。港投公司目前管 理香港增长组合、大湾区投资基金、策略性创科基金和共同投资基金。现阶段选定三大主要投资赛道， 为硬科技、生命科技、新能源和绿色科技。截至2024年末，港投公司总资产规模超640亿港元。 普洛斯中国区首席战略官、隐山资本董事长及管理合伙人东方浩表示："隐山资本将凭借在物流供应 链、人工智能、机器人技术以及可再生能源等新经济领域中积累的产业洞察，发掘拥有前沿技术和规模 化应用潜力的创新企业，助力港投公司生态圈可持续扩展，并取得协同发展。" 中证报中证网讯(记者黄一灵)12月9日，普洛斯旗下私募股权投资平台隐山资本宣布获得香港投资管理 有限公司(下称"港投公司")委托管理3亿港元基金。 据介绍，该基金属于香港特别行政区政府"新资本投资者入境计划"下"投资组合"2025资金组别，将投向 早期阶段、具有高增长潜力的企业。 ...

来源：嘉御资本 每日｜荐读 论坛： 新一批敲钟人，已在路上 荐读： 重新发现香港：科创时代的新蓝图 榜单： 全国首只AIC产业母基金来了 热文： 投资人"忙疯了" 2025年12月5日， 嘉御资本2025年投资人年会在上海陆家嘴成功举办。大会上，嘉御资本宣布完成多支新基金的募集设立，总规模超过40亿元人 民币。参与基金的主要投资人包括长沙、宁波、天津和长三角地区等高度市场化的引导基金、生态联动的上市公司产业资本和市场领先的人民币母基 金，以及多位基金老投资人的持续支持。 据悉，本次新募集的基金矩阵，全面覆盖了嘉御资本前瞻布局的领域，包括AI基础建设、新消费产业、跨境电商品牌出海、生命科技等多个核心赛 道，旨在系统性地把握中美AI"软硬兼施"、全球供应链重构及新消费范式下的结构性机会，形成协同有力的投资生态体系。 ...

随着2026年即将成立15周年之际，嘉御资本也将迎来有史以来最为密集的IPO收获期。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，嘉御资本2025年投资人年会日前在上海陆家嘴成功举办。大会上，嘉御资本宣 布完成多支新基金的募集设立，总规模超过40亿元人民币。参与基金的主要投资人包括长沙、宁 波、天津和长三角地区等高度市场化的引导基金、生态联动的上市公司产业资本和市场领先的人民币 母基金，以及多位基金老投资人的持续支持。 嘉御资本创始合伙人、董事长卫哲先生表示："感谢所有新老投资人的信任。投资就是传递信任，嘉 御资本14年来始终秉承'以终为始'和不变的3R原则，恪守为投资人创造回报（Return）、严控风险 （Risk）、赢得多方尊重（Respect）的初心所在。" 在当前全球和中国经济步入存量时代，而科技革命驶入"快车道"的交叉口，拐点初现，把握新机。 本次新募集的基金矩阵，全面覆盖了嘉御资本前瞻布局的领域，包括AI基础建设、新消费产业、跨境 电商品牌出海、生命科技等多个核心赛道，旨在系统性地把握中美AI"软硬兼施"、全球供应链重构 及新消费范 ...

Core Viewpoint - Hong Kong Investment Management Company (HKIMC), known as the "Hong Kong version of Temasek," reported its first annual report, showing an investment income of HKD 2.345 billion for 2024, with an operating profit of HKD 2.252 billion after deducting operating expenses of HKD 93 million [2][11]. Financial Performance - Investment income for the year ending December 31, 2024, was HKD 2,345 million - Operating expenses totaled HKD 93 million, which included: - Employee and related costs: HKD 43 million - Legal and professional fees: HKD 19 million - Other operating expenses: HKD 18 million - Depreciation: HKD 13 million - Operating profit reached HKD 2,252 million [4][11]. Investment Strategy - 62% of the capital was allocated to projects in mainland China, 34% in Hong Kong, and 4% in other regions [5][7]. - By investment theme, hard technology accounted for 71%, life sciences for 13%, and renewable and green technology for 11%, with other themes making up 5% [8]. - 69% of the funds were directed towards growth-stage companies, 21% towards mature companies, and 10% towards early-stage companies [10]. Market Impact - The investments made by HKIMC have created over 6,400 jobs in Hong Kong and leased 268,000 square meters of office space, while also registering 109 intellectual properties in the region [10]. - The company has seen two of its portfolio companies go public, with over ten others having submitted or preparing to submit IPO applications, including five unicorns prior to their listings [10]. Leadership and Compensation - The average annual salary for employees at the director level or above was HKD 4.7 million, with the CEO's salary being HKD 7.2 million [11].

Core Insights - Ronghe Medical Technology (Zhejiang) Co., Ltd. has completed a Series B financing round led by Qiming Venture Partners, with funds aimed at accelerating the clinical promotion and market expansion of its innovative "real-time electromagnetic navigation bronchial rheoplasty" technology for chronic obstructive pulmonary disease (COPD) [1][1][1] Company Overview - Ronghe Medical has developed the Breeze One® "real-time electromagnetic navigation pulsed electric field ablation system," which received FDA breakthrough device designation in April 2025 [1][1] - The company emphasizes its commitment to exploring life sciences and enhancing core innovative technologies to create significant clinical value [1][1] Investment Perspective - Qiming Venture Partners recognizes Ronghe Medical's original innovation in the field of COPD intervention, highlighting its clear clinical mechanisms and significant efficacy advantages, as well as its global competitiveness in "Chinese manufacturing" [1][1] - Huatang Venture Capital views Ronghe Medical as a model project of "medical-engineering integration," with high technical barriers and clinical recognition, and expresses anticipation for the company's global product expansion [1][1] Future Directions - Ronghe Medical plans to focus on the forefront of life sciences, integrating and expanding its core technology matrix to develop original medical device solutions with significant clinical value [1][1] - The company aims to enhance accessibility and equity in respiratory disease diagnosis and treatment, contributing to a more efficient and fair public health system [1][1]

Core Viewpoint - The article highlights the upcoming 15th China Venture Capital and Private Equity Annual Forum, emphasizing its role as a significant event for industry leaders and investment professionals to discuss trends and opportunities in the venture capital space [2][8]. Event Overview - The forum will take place from December 2 to December 5, 2025, in Shenzhen, China, featuring various sessions and discussions aimed at exploring the future of investment and innovation [3][24]. - The event will include a series of thematic exploration stations, such as "AI Deep Dive" and "Life Force Island," focusing on cutting-edge industries and health futures [9][12][13]. Key Activities - The agenda includes a mix of keynote speeches, panel discussions, and networking opportunities, with notable sessions like the "Investment Trends Forum" and "Innovation Drug and Life Science Summit" scheduled [24][25]. - A special "X-Day" event will showcase global technology innovations, providing a platform for startups and investors to connect [25]. Networking Opportunities - The forum aims to gather over a thousand investment elites and industry leaders, facilitating discussions on investment strategies and market trends [8][10]. - Various social events, including a gala dinner and sports activities, are planned to enhance networking among participants [25][26].

Core Insights - The 2025 International Conference for Scientists will be held from November 7-9, 2025, in Changsha, Hunan, focusing on "A New Era in Life Sciences: Reshaping the Future of Human Health" [1] - The conference aims to gather over 3,000 participants, including Nobel laureates, academicians, and leading figures in the medical and health sectors, to create a high-level interdisciplinary exchange platform [8][13] Group 1: Conference Details - The conference will feature ten parallel forums covering key topics such as enzyme technology, cell technology, diabetes, frontier technologies in life sciences, microecology, tumor and immunotherapy, precision nutrition, artificial intelligence in health management, health industry and innovation investment, and cosmetics technology [13] - The event is positioned in Changsha, a rising global R&D center and a significant national research base, which has become an innovative hub for the integration of life sciences and intelligent industries [8] Group 2: Key Participants and Contributions - Shandong Ming, Vice President of Shanghai Information Investment Co., and Chairman of Shanghai Kupar Technology Co., will serve as the chair of the Artificial Intelligence and Health Data Management Forum, bringing valuable industry insights [1][7] - Shandong Ming has extensive experience in digital transformation and policy formulation, having contributed to multiple five-year plans for Shanghai's information development [5][3] Group 3: Focus on Health Data - The conference will emphasize the creation of an innovative ecosystem for health data circulation, exploring how to unlock the potential value of medical health data while ensuring data security and privacy [7] - The event aims to provide guidance on the compliant circulation and value extraction of health data elements, contributing to the establishment of a safe, efficient, and trustworthy health data innovation application system [7]

Core Viewpoint - The company, Dinggu Jichuang (300749.SZ), is strategically expanding its investment activities into emerging industries by leveraging professional investment institutions to enhance its insights into these sectors and incubate more projects [1] Group 1: Investment Strategy - The company plans to engage in equity investments in emerging industries while maintaining its core business focus [1] - A total of RMB 3 million will be invested as a limited partner in the "Muhua Shuijing (Shanghai) Venture Capital Partnership" [1] - The partnership agreement was signed on October 20, 2025, with Waterwood Huqing (Beijing) Venture Capital Fund Management Co., Ltd. and other partners [1] Group 2: Investment Focus Areas - The investment fields include but are not limited to artificial intelligence, embodied intelligence, new energy materials, advanced manufacturing, semiconductors, and life sciences [1] - Investment methods will encompass equity investments, convertible bond investments with applicable legal conditions, and other legally permissible investment methods [1]

Core Viewpoint - The article highlights the upcoming 15th China Venture Capital Annual Conference, emphasizing its significance in the investment landscape and the diverse topics to be discussed, including trends in venture capital and private equity [2][3]. Event Highlights - The conference will feature over 200 investors and 300+ investment firms, showcasing a significant turnout and engagement in the investment community [6]. - Key events include the "Investment Trends Forum," AI Summit, and "Investment iTalk," focusing on practical insights and discussions rather than theoretical concepts [9][10]. Agenda Overview - The agenda includes a series of keynote speeches, panel discussions, and networking opportunities, starting with the opening ceremony and the release of the "2025 China Venture Capital Development Report" [12][14]. - Notable sessions include discussions on angel investing, investment cycles, and the challenges and opportunities in hard technology investments [17][20]. Special Activities - The conference will also host special activities such as a CEO breakfast meeting, a half-marathon, and various sports events, promoting networking in a more casual environment [18][22][24]. - The "X-Day" overseas consumer electronics project roadshow will provide a platform for showcasing innovative projects to potential investors [19]. Registration and Participation - Ticket pricing is structured to accommodate different participants, with early bird and group discounts available, ensuring accessibility for a wide range of attendees [25].